NCT04366921

Brief Summary

In the last 10 years, severe acute respiratory infection (SARI) was responsible of multiple outbreaks putting a strain on the public health worldwide. Indeed, SARI had a relevant role in the development of pandemic and epidemic with terrible consequences such as the 2009 H1N1 pandemic which led to more than 200.000 respiratory deaths globally. In late December 2019, in Wuhan, Hubei, China, a new respiratory syndrome emerged with clinical signs of viral pneumonia and person-to-person transmission. Tests showed the appearance of a novel coronavirus, namely the 2019 novel coronavirus (COVID-19). Two other strains, the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have caused severe respiratory illnesses, sometimes fatal. In particular, the mortality rate associated with SARS-CoV and MERS-CoV, was of 10% and 37% respectively. Even though COVID-19 appeared from the first time in China, quickly it spread worldwide and cases have been described in other countries such as Thailand, Japan, South Korea, Germany, Italy, France, Iran, USA and many other countries. An early paper reported 41 patients with laboratory-confirmed COVID-19 infection in Wuhan. The median age of the patients was 49 years and mostly men (73%). Among those, 32% were admitted to the ICU because of the severe hypoxemia. The most associated comorbidities were diabetes (20%), hypertension (15%), and cardiovascular diseases (15%). On admission, 98% of the patients had bilateral multiple lobular and sub-segmental areas of consolidation. Importantly, acute respiratory distress syndrome (ARDS) developed in 29% of the patients, while acute cardiac injury in 12%, and secondary infection in 10%. Invasive mechanical ventilation was required in 10% of those patients, and two of these patients (5%) had refractory hypoxemia and received extracorporeal membrane oxygenation (ECMO). In a later retrospective report by Wang and collaborators, clinical characteristics of 138 patients with COVID-19 infection were described. ICU admission was required in 26.1% of the patients for acute respiratory distress syndrome (61.1%), arrhythmia (44.4%), and shock (30.6%). ECMO support was needed in 11% of the patients admitted to the ICU. During the period of follow-up, overall mortality was 4.3%. The use of ECMO in COVID-19 infection is increasing due to the high transmission rate of the infection and the respiratory-related mortality. Therefore, the investigators believe that ECMO in case of severe interstitial pneumonia caused by COVID could represent a valid solution in order to avoid lung injuries related to prolonged treatment with non-invasive and invasive mechanical ventilation. In addition, ECMO could have a role for the systemic complications such as septic and cardiogenic shock as well myocarditis scenarios. Potential clinical effects and outcomes of the ECMO support in the novel coronavirus pandemic will be recorded and analyzed in our project. The researchers hypothesize that a significant percentage of patients with COVID-19 infection will require the utilize of ECMO for refactory hypoxemia, cardiogenic shock or septic shock. This study seeks to prove this hypothesis by conducting an observational retrospective/prospective study of patients in the ICU who underwent ECMO support and describe clinical features, severity of pulmonary dysfunction and risk factors of COVID-patients who need ECMO support, the incidence of ECMO use, ECMO technical characteristics, duration of ECMO, complications and outcomes of COVID-patients requiring ECMO support.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2020

Geographic Reach
19 countries

97 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 10, 2020

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

April 17, 2020

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 29, 2020

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2022

Completed
Last Updated

September 5, 2021

Status Verified

August 1, 2021

Enrollment Period

2 years

First QC Date

April 17, 2020

Last Update Submit

September 3, 2021

Conditions

COVIDSARS-CoV-2ARDS, HumanRefractory HypoxemiaCardiogenic ShockSeptic ShockExtracorporeal Membrane Oxygenation

Outcome Measures

Primary Outcomes (34)

  • Age

    age in years

    at baseline

  • Gender

    male/female

    at baseline

  • Weight

    in kilograms

    at baseline

  • Height

    in meters

    at baseline

  • BMI

    weight and height combined to calculate BMI in kg/m\^2

    at baseline

  • Pre-existing pulmonary disease y/n

    Asthma y/n, cystic fibrosis y/n, chronic obstructive pulmonary disease y/n, pulmonary hypertension y/n, pulmonary fibrosis y/n, chronic restrictive lung disease y/n

    at baseline

  • Main co-morbidities y/n

    diabetes mellitus y/n, chronic renal failure y/n, ischemic heart disease y/n, heart failure y/n, chronic liver failure y/n, neurological impairment y/n

    at baseline

  • Date of signs of COVID-19 infection

    in dd-mm-yyyy or mm-dd-yyyy

    at baseline or date of occurence

  • Date of positive swab

    in dd-mm-yyyy or mm-dd-yyyy

    at baseline or date of occurence

  • Pre-ECMO length of hospital stay

    in days

    at or during ECMO-implant

  • Pre-ECMO length of ICU stay

    in days

    at or during ECMO-implant

  • Pre-ECMO length of mechanical ventilation days

    in days

    at or during ECMO-implant

  • Use of antibiotics

    y/n, what kind

    up to 6 months

  • Use of anti-viral treatment

    y/n, what kind

    up to 6 months

  • Use of second line treatment

    y/n, what kind (eg prone-position, recruitment manoeuvers, neuromuscular blockade etc)

    up to 6 months

  • Indications for ECMO-implant

    respiratory or cardiac

    at ECMO-implant

  • Type of ECMO-implant

    veno-venous, veno-arterial or veno-venoarterial

    at ECMO-implant

  • Type of access

    peripheral or central

    at ECMO-implant

  • Date of ECMO implant

    in dd-mm-yyyy or mm-dd-yyyy

    at ECMO-implant

  • ECMO blood flow rate

    l/min

    from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

  • ECMO gas flow rate

    l/min

    from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

  • ECMO configuration change

    y/n

    up to 6 months

  • Date of ECMO configuration change

    in dd-mm-yyyy or mm-dd-yyyy

    up to 6 months

  • New ECMO configuration

    veno-venous, veno-arterial, veno-venoarterial, other

    up to 6 months

  • Indications for ECMO configuration change

    right ventricular failure, left ventricular failure, refractory hypoxemia

    up to 6 months

  • Ventilator setting on ECMO

    settings of ventilator

    from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

  • Anticoagulation during ECMO

    heparin, bivalirudin, nothing

    from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

  • Frequency of ECMO circuit change

    amount of ECMO circuit changes (1, 2, 3 etc.)

    up to 6 months

  • ECMO complications

    Hemorrhagic, infection, other complications

    up to 6 months

  • ECMO Weaning

    y/n

    from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

  • ICU discharge

    y/n, date

    from day of ICU-admission for every 24 hours until date of discharge or death, up to 6 months

  • Main cause of death

    6 months

  • Type of discharge

    Ward, another ICU, rehabilitation center, home

    up to 6 months

  • Alive/deceased

    6 months

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with confirmed COVID-19 infection who require ECMO support

You may qualify if:

  • Laboratory-confirmed COVID-19 infection by real-time PCR (polymerase chain reaction)
  • ECMO for treatment severe lung disease COVID-19 related

You may not qualify if:

  • Patients treated with ECMO for other concomitant causes.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (97)

Universitätskliniken Innsbruck

Innsbruck, Austria

RECRUITING

Landesklinikum Sankt Polten

Sankt Pölten, Austria

RECRUITING

Medical University of Vienna

Vienna, Austria

RECRUITING

Onze Lieve Vrouwziekenhuis Aalst

Aalst, Belgium

RECRUITING

University Hospital, Antwerp

Antwerp, Belgium

RECRUITING

Centre Hospitalier Universitaire Saint Pierre

Brussels, Belgium

RECRUITING

Chirec

Brussels, Belgium

RECRUITING

Erasme University Hospital

Brussels, Belgium

RECRUITING

Universitair Ziekenhuis Brussel

Brussels, Belgium

RECRUITING

Hôpital Civil Marie Curie de Charleroi

Charleroi, Belgium

RECRUITING

University Hospital, Ghent

Ghent, Belgium

RECRUITING

La Louvière Hopital

La Louvière, Belgium

RECRUITING

Universitaire Ziekenhuizen Leuven

Leuven, Belgium

RECRUITING

CHU de Liege

Liège, Belgium

RECRUITING

Charles University, Czech Republic

Prague, Czechia

RECRUITING

General University Hospital, Prague

Prague, Czechia

RECRUITING

Copenhagen University Hospital at Herlev

Copenhagen, Denmark

RECRUITING

University Hospital, Bordeaux

Bourdeaux, France

RECRUITING

Hospices Civils de Lyon

Lyon, France

RECRUITING

University Hospital, Montpellier

Montpellier, France

RECRUITING

Henri Mondor University Hospital

Paris, France

RECRUITING

Paris South University Hospitals

Paris, France

RECRUITING

Pitié-Salpêtrière Hospital

Paris, France

RECRUITING

Rennes University Hospital

Rennes, France

RECRUITING

University Hospital, Aachen

Aachen, Germany

RECRUITING

German Heart Center

Berlin, Germany

RECRUITING

Universitätsklinikum Köln

Cologne, Germany

RECRUITING

Universitätsklinikum Düsseldorf

Düsseldorf, Germany

RECRUITING

Children's Medical Hospital, University of Essen, Essen, Germany

Essen, Germany

RECRUITING

University Hospital, Essen

Essen, Germany

RECRUITING

University Heart Center Freiburg - Bad Krozingen

Freiburg im Breisgau, Germany

RECRUITING

Hannover Medical School

Hanover, Germany

RECRUITING

Klinikum Kassel

Kassel, Germany

RECRUITING

Heart Center Leipzig - University Hospital

Leipzig, Germany

RECRUITING

Klinikum Nürnberg

Nuremberg, Germany

RECRUITING

University Hospital Regensburg

Regensburg, Germany

RECRUITING

University Hospital Tuebingen

Tübingen, Germany

RECRUITING

University Hospital, Alexandroupolis

Alexandroupoli, Greece

RECRUITING

Heim Pal Children's Hospital

Budapest, Hungary

RECRUITING

ECMO Centers Israel

Jerusalem, Israel

RECRUITING

San Giorgio Clinic

Alessandria, Italy

RECRUITING

Ospedali Riuniti Ancona

Ancona, Italy

RECRUITING

Papa Giovanni XXIII Hospital

Bergamo, Italy

RECRUITING

St. Orsola Hospital

Bologna, Italy

RECRUITING

Azienda Ospedaliera Spedali Civili di Brescia

Brescia, Italy

RECRUITING

Ospedale Maurizio Bufalini

Cesena, Italy

RECRUITING

Gaslini Children's Hospital

Genoa, Italy

RECRUITING

G. Pasquinucci Heart Hospital, Massa

Massa, Italy

RECRUITING

Niguarda Hospital

Milan, Italy

RECRUITING

Ospedale San Donato

Milan, Italy

RECRUITING

San Raffaele University Hospital, Italy

Milan, Italy

RECRUITING

Policlinico Hospital Milan

Milan, Italy

RECRUITING

San Gerardo Hospital

Monza, Italy

RECRUITING

IRCCS Policlinico S. Matteo

Pavia, Italy

RECRUITING

GVM Care & Research

Puglia, Italy

RECRUITING

Bambino Gesù Hospital and Research Institute

Roma, Italy

RECRUITING

San Camillo Hospital, Rome

Roma, Italy

RECRUITING

A.O.U. Città della Salute e della Scienza - Molinette Hospital

Turin, Italy

RECRUITING

Mauriziano Umberto I Hospital

Turin, Italy

RECRUITING

Ospedale S. Giovanni Bosco

Turin, Italy

RECRUITING

University Hospital, Udine, Italy

Udine, Italy

RECRUITING

Ospedale dell'Angelo, Venezia-Mestre

Venice, Italy

RECRUITING

Ospedale San Bortolo di Vicenza

Vicenza, Italy

RECRUITING

Vilnius University Hospital Santaros Klinikos

Vilnius, Lithuania

RECRUITING

University of Groningen

Groningen, Netherlands

RECRUITING

Leiden University Medical Center

Leiden, Netherlands

RECRUITING

Maastricht University Medical Center

Maastricht, Netherlands

RECRUITING

Erasmus Medical Center

Rotterdam, Netherlands

RECRUITING

UMC Utrecht

Utrecht, Netherlands

RECRUITING

Medical University of Warsaw

Warsaw, Poland

RECRUITING

Hospital Sao Joao

Porto, Portugal

RECRUITING

Chelyabinsk Regional Clinical Hospital

Chelyabinsk, Russia

RECRUITING

Kemerovo Regional Clinical Cardiological Center named after academician L.S. Barbarash

Kemerovo, Russia

RECRUITING

Krasnodar Regional Hospital no 1

Krasnodar, Russia

RECRUITING

City Clinical Hospital No. 67, Moscow, Russia

Moscow, Russia

RECRUITING

Novosibirsk City Hospital #2

Novosibirsk, Russia

RECRUITING

City Hospital No 40, Saint Petersburg, Russia

Saint Petersburg, Russia

RECRUITING

City Hospital No 41, Ekaterinburg, Russia

Yekaterinburg, Russia

RECRUITING

Hospital Sant Joan de Deu

Barcelona, Spain

RECRUITING

Hospital Vall d'Hebron

Barcelona, Spain

RECRUITING

Hospital Universitario Ramon y Cajal

Madrid, Spain

RECRUITING

Hospital Miguel Servet

Zaragoza, Spain

RECRUITING

Lund University Hospital

Lund, Sweden

RECRUITING

Karolinska University Hospital

Stockholm, Sweden

RECRUITING

University Hospital, Basel, Switzerland

Basel, Switzerland

RECRUITING

University of Bern

Bern, Switzerland

RECRUITING

University Hospital, Geneva

Geneva, Switzerland

RECRUITING

University of Lausanne Hospitals

Lausanne, Switzerland

RECRUITING

Cardiocentro Ticino

Lugano, Switzerland

RECRUITING

Klinik Hirslanden, Zurich

Zurich, Switzerland

RECRUITING

University of Zurich

Zurich, Switzerland

RECRUITING

Royal Brompton & Harefield NHS Foundation Trust

Brompton, United Kingdom

RECRUITING

Paediatric Intensive Care Glasgow

Glasgow, United Kingdom

RECRUITING

Leicester Children's Hospital

Leicester, United Kingdom

RECRUITING

Great Ormond Street Hospital for Children NHS Foundation Trust

London, United Kingdom

RECRUITING

Guy's and St Thomas' NHS Foundation Trust

London, United Kingdom

RECRUITING

Newcastle-upon-Tyne Hospitals NHS Trust

Newcastle upon Tyne, United Kingdom

RECRUITING

Related Publications (15)

  • Bolotin S, Pebody R, White PJ, McMenamin J, Perera L, Nguyen-Van-Tam JS, Barlow T, Watson JM; UK Severe Influenza Surveillance System (USISS) Steering Group. A new sentinel surveillance system for severe influenza in England shows a shift in age distribution of hospitalised cases in the post-pandemic period. PLoS One. 2012;7(1):e30279. doi: 10.1371/journal.pone.0030279. Epub 2012 Jan 23.

    PMID: 22291929BACKGROUND

  • Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Feikin DR, Fowler KB, Gordon A, Hien NT, Horby P, Huang QS, Katz MA, Krishnan A, Lal R, Montgomery JM, Molbak K, Pebody R, Presanis AM, Razuri H, Steens A, Tinoco YO, Wallinga J, Yu H, Vong S, Bresee J, Widdowson MA. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012 Sep;12(9):687-95. doi: 10.1016/S1473-3099(12)70121-4. Epub 2012 Jun 26.

    PMID: 22738893BACKGROUND

  • Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, Van Kerkhove MD, Mounts AW, Paget WJ; GLaMOR Collaborating Teams. Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. PLoS Med. 2013 Nov;10(11):e1001558. doi: 10.1371/journal.pmed.1001558. Epub 2013 Nov 26.

    PMID: 24302890BACKGROUND

  • Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.

    PMID: 31986261BACKGROUND

  • Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003 May 15;348(20):1967-76. doi: 10.1056/NEJMoa030747. Epub 2003 Apr 10.

    PMID: 12690091BACKGROUND

  • Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ; SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003 May 15;348(20):1953-66. doi: 10.1056/NEJMoa030781. Epub 2003 Apr 10.

    PMID: 12690092BACKGROUND

  • Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012 Nov 8;367(19):1814-20. doi: 10.1056/NEJMoa1211721. Epub 2012 Oct 17.

    PMID: 23075143BACKGROUND

  • de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013 Jul;87(14):7790-2. doi: 10.1128/JVI.01244-13. Epub 2013 May 15. No abstract available.

    PMID: 23678167BACKGROUND

  • Spina S, Marrazzo F, Migliari M, Stucchi R, Sforza A, Fumagalli R. The response of Milan's Emergency Medical System to the COVID-19 outbreak in Italy. Lancet. 2020 Mar 14;395(10227):e49-e50. doi: 10.1016/S0140-6736(20)30493-1. Epub 2020 Feb 28. No abstract available.

    PMID: 32119824BACKGROUND

  • Ebrahim SH, Memish ZA. COVID-19: preparing for superspreader potential among Umrah pilgrims to Saudi Arabia. Lancet. 2020 Mar 14;395(10227):e48. doi: 10.1016/S0140-6736(20)30466-9. Epub 2020 Feb 27. No abstract available.

    PMID: 32113506BACKGROUND

  • Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.

    PMID: 32004427BACKGROUND

  • Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.

    PMID: 31986264BACKGROUND

  • Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.

    PMID: 32031570BACKGROUND

  • De Piero ME, Mariani S, van Bussel BCT, Jarczak D, Krenner N, de la Sota EP, Silva PE, Roemmer M, Kowalewski M, Carelli S, Broman LM, Vuylsteke A, Fortuna P, Alessandri F, Martucci G, Patel BV, Lotz G, Boeken U, Maier S, Filip B, Meyns B, Haenggi M, Puss S, Schellongowski P, Kirali K, Bolotin G, Barrett N, Riera J, Mueller T, Belohlavek J, Lorusso R; EuroECMO-COVID Study Group. In-hospital outcomes and 6-month follow-up results of patients supported with extracorporeal membrane oxygenation for COVID-19 from the second wave to the end of the pandemic (EuroECMO-COVID): a prospective, international, multicentre, observational study. Lancet Respir Med. 2025 Apr;13(4):307-317. doi: 10.1016/S2213-2600(24)00369-2. Epub 2025 Feb 23.

    PMID: 40010369DERIVED

  • Lorusso R, De Piero ME, Mariani S, Di Mauro M, Folliguet T, Taccone FS, Camporota L, Swol J, Wiedemann D, Belliato M, Broman LM, Vuylsteke A, Kassif Y, Scandroglio AM, Fanelli V, Gaudard P, Ledot S, Barker J, Boeken U, Maier S, Kersten A, Meyns B, Pozzi M, Pedersen FM, Schellongowski P, Kirali K, Barrett N, Riera J, Mueller T, Belohlavek J; EuroECMO-COVID Study Group. In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study. Lancet Respir Med. 2023 Feb;11(2):151-162. doi: 10.1016/S2213-2600(22)00403-9. Epub 2022 Nov 16.

    PMID: 36402148DERIVED

MeSH Terms

Conditions

Respiratory Distress SyndromeHypoxiaShock, CardiogenicShock, Septic

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiration DisordersSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsMyocardial InfarctionMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesNecrosisShockSepsisInfectionsSystemic Inflammatory Response SyndromeInflammation

Study Officials

  • Lorusso, Prof. Dr.

    Maastricht University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Lorusso, Prof. Dr.

CONTACT

+ 31(0) 433877095roberto.lorussobs@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 17, 2020

First Posted

April 29, 2020

Study Start

April 10, 2020

Primary Completion

April 1, 2022

Study Completion

April 1, 2022

Last Updated

September 5, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations

GB(6)AU(3)HU(1)LI(1)NL(5)CH(7)BE(11)PL(1)IL(1)ES(4)IT(23)DK(1)DE(13)GR(1)RU(7)SE(2)PT(1)CZ(2)FR(7)